Industry Bulletins | June 22, 2018
Johnson & Johnson Accepts $2.1 Billion Bid For Its LifeScan Diabetes Business
Johnson & Johnson (J&J) recently accepted a $2.1 billion offer from Platinum Equity for its LifeScan diabetes unit. Platinum Equity is a global firm specializing in mergers, acquisitions, and operations of companies that provide mission-critical products, services, and solutions.
With sales of its diabetes product companies falling over the past several years, J&J has previously stated it was exploring business options. It is expected that the deal will close by the end of the year. LifeScan generated about $1.5 billion in revenue during 2017.
Johnson & Johnson is an American multinational medical devices . . .